Literature DB >> 1858783

Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura.

J W Semple1, S Bruce, J Freedman.   

Abstract

Natural killer (NK) cell activity was studied in 17 patients with primary chronic idiopathic autoimmune thrombocytopenic purpura (ATP). Fifteen of 17 patients had a significantly reduced NK cytotoxicity against 51chromium labeled K562 target cells (mean LU20% = 18 +/- 20 in patients versus 65 +/- 25 in controls, P less than 0.001). NK activity was also significantly reduced in all of six patients with secondary ATP as compared with normal controls (LU20% 28 +/- 15, respectively, P less than 0.005). The NK activity in both patient groups correlated with the duration of therapy being received (r = 0.60, P less than 0.001). Immunophenotypic analysis of peripheral blood mononuclear cells from patients with ATP revealed that CD8- cells bearing CD57 (HNK-1, Leu 7) and CD3- cells bearing CD56 (Leu 19) were quantitatively within the normal range. These findings indicate that patients with ATP have a functional defect in NK cytolytic activity.

Entities:  

Mesh:

Year:  1991        PMID: 1858783     DOI: 10.1002/ajh.2830370409

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients.

Authors:  R Giacomelli; A Passacantando; G Frieri; I Parzanese; S D'Alò; P Vernia; M T Pimpo; C Petrucci; R Caprilli; M G Cifone; G Tonietti
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

3.  Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia.

Authors:  Zhenhua Zhao; Lei Yang; Guohua Yang; Yun Zhuang; Xifeng Qian; Xin Zhou; Dajiang Xiao; Yunfeng Shen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

Review 4.  The Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and Pathogenesis.

Authors:  Rita Consolini; Annalisa Legitimo; Maria Costanza Caparello
Journal:  Front Pediatr       Date:  2016-10-19       Impact factor: 3.418

5.  Assessment of regulatory T cells in childhood immune thrombocytopenic purpura.

Authors:  Karina L M Mazzucco; Lauro M Junior; Natália E Lemos; Andréa Wieck; Annelise Pezzi; Alvaro M Laureano; Bruna Amorin; Vanessa Valim; Lucia Silla; Liane E Daudt; Paulo J C Marostica
Journal:  ISRN Hematol       Date:  2013-11-05

Review 6.  Emerging Concepts in Immune Thrombocytopenia.

Authors:  Maurice Swinkels; Maaike Rijkers; Jan Voorberg; Gestur Vidarsson; Frank W G Leebeek; A J Gerard Jansen
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.